Evidence map›Paper›PMID 32371459›Full record

ArticleJournal for immunotherapy of cancer2020

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.

Quan Zhou, Yangyang Qi, Zewei Wang, Han Zeng, Hongyu Zhang, Zhaopei Liu, Qiuren Huang, Ying Xiong, Jiajun Wang, Yuan Chang and 10 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01358721 (An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01358721 phase1completednot on this map

An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

TypeinterventionalSponsorBristol-Myers SquibbRan2011 to 2019Enrolled119ConditionsRenal Cell CarcinomaArmsBMS-936558 (Anti-PD-1)
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  10. Article
  11. Article
  12. BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Quan Zhou *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yangyang Qi *Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zewei Wang *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Han Zeng *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hongyu ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhaopei LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Qiuren HuangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Ying XiongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiajun WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qi BaiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu XiaDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yiwei WangDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li LiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bo DaiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China jjxufdu@fudan.edu.cn weijuanzhang@fudan.edu.cn yuzhu10@fudan.edu.cn.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn weijuanzhang@fudan.edu.cn yuzhu10@fudan.edu.cn.ORCID 0000-0003-3494-3114
Jiejie XuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn weijuanzhang@fudan.edu.cn yuzhu10@fudan.edu.cn.ORCID 0000-0001-7431-9063
Fudan University · CNSun Yat-sen University · CNFudan University Shanghai Cancer Center · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with BRCA1-associated protein 1 (BAP1)-mutant clear cell renal cell carcinoma (ccRCC) have worse prognosis. C-C chemokine receptor 5 (CCR5) plays an important role in ccRCC development and its expression is elevated in BAP1-mutant tumors.

methods533 patients with ccRCC from The Cancer Genome Atlas cohort and 797 patients with ccRCC from the Shanghai cohort were enrolled. In vitro and in vivo studies were conducted with human ccRCC tumors and murine tumor models. The association between BAP1 and CCR5 or its ligands was assessed by immunohistochemistry, flow cytometry, real-time PCR and ELISA. Survival was compared between different subpopulations of patients using Kaplan-Meier curve. Therapeutic effect of CCR5 blockade was validated using human ccRCC tumors and murine models.

resultsExpression of CCR5 and its ligands were elevated in BAP1-mutant patients with ccRCC. High CCR5 expression was indicative of poor prognosis in BAP1-low group of patients. CCR5 blockade prolonged the survival of tumor-bearing mice, resulting in enhanced cytotoxicity of T cells and antigen presentation of dendritic cells but repressed immune checkpoint expression. CCR5 ligands could recruit CCR5

conclusionsCCR5 in BAP1-mutant ccRCC results in an immune-suppressive microenvironment. Targeting CCR5 could provide a potential therapeutic benefit for patients. TRIAL REGISTRATION NUMBER: NCT01358721, CA209-009.

Indexed as

AgedAnimalsAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellCell Line, TumorChemotherapy, AdjuvantDisease-Free SurvivalDisease Models, AnimalDNA Mutational AnalysisFemaleFollow-Up StudiesHumansKidney NeoplasmsMaleMiddle AgedMutationAntineoplastic Agents, ImmunologicalBAP1 protein, humanCCR5 protein, humanCCR5 protein, mouseReceptors, CCR5Tumor Suppressor ProteinsUbiquitin Thiolesteraseimmunologyoncologyurology

Identifiers

PMID32371459
PMCPMC7228663
OpenAlexW3023695045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.